{
    "clinical_study": {
        "@rank": "102340", 
        "acronym": "PTCL-06", 
        "arm_group": [
            {
                "arm_group_label": "Clin A", 
                "arm_group_type": "Experimental", 
                "description": "Clin A. CHOP-Campath (CHOP-C) for 2 cycles , Hyper-C-Hidam for 2 cycles and  auto-SCT (stem cell transplantation) or RIC allo-SCT in advanced stage PTCL pts \u2265 18 and \u2264 60 years"
            }, 
            {
                "arm_group_label": "Clin B", 
                "arm_group_type": "Experimental", 
                "description": "Clin B: CHOP-Campath (CHOP-C) for 6 cycles . It is a combined immunochemotherapy approach in a subset of elderly pts aged > 60 \u2264 75 years"
            }
        ], 
        "brief_summary": {
            "textblock": "Peripheral T cell lymphomas (PTCL) are a rare hematologic disease. Five-year overall\n      survival (OS) of PTCL patients (pts) ranges between 20 and 30%. Allogeneic stem cell\n      transplantation (allo-STC) may have a curative role for these pts but its toxicity is high\n      when myeloablative conditioning is used. Reduced intensity conditionings (RIC) can decrease\n      transplant related toxicity and mortality. The investigators have recently proved\n      feasibility and potential efficacy of a RIC regimen in relapsed PTCL patients.\n\n      We want to investigate whether it is possible to improve the outcome of alk negative PTCL\n      pts, stage II-IV at diagnosis, by intensifying the therapeutic approach.\n\n      The intensification will be obtained by combining intensive chemotherapy, alemtuzumab\n      (anti-CD52 humanised antibody) and auto- or allo-SCT in pts aged between 18 and 60 years\n      (Clinical Study A) or adding alemtuzumab to standard chemotherapy (CHOP) in pts aged between\n      61 and 70 years(Clinical Study B)."
        }, 
        "brief_title": "Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma", 
        "completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "condition": "Lymphoma, T-Cell, Peripheral", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, T-Cell", 
                "Lymphoma, T-Cell, Peripheral"
            ]
        }, 
        "detailed_description": {
            "textblock": "Inclusion criteria Clin A\n\n        -  Age \u226518  < or =60 years (patients older than 60 years are excluded because of the\n           intensive chemotherapy and transplant procedures)\n\n        -  Histologically proven diagnosis of PTCL, including the following categories: PTCL-U\n           (peripheral T-cell lymphoma, unspecified), AILD-T (angioimmunoblastic-like T-cell\n           lymphoma), ALKneg ALCL (ALK-negative anaplastic large cell lymphoma),intestinal T - NHL\n\n        -  Advanced stage disease (stage II-IV) or stage I and aaIPI score \u2265 2\n\n        -  Written informed consent\n\n      Inclusion criteria Clin B\n\n        -  Age >60 and \u226475 years (patients older than 75 years are excluded because of the\n           intensive chemo-immunotherapy program)\n\n        -  Histological proven diagnosis of PTCL, including the following categories: PTCL-U\n           (peripheral T-cell lymphoma, unspecified), AILD-T (angioimmunoblastic-like T-cell\n           lymphoma), ALKneg ALCL (ALK-negative anaplastic large cell lymphoma), intestinal T -\n           NHL\n\n        -  Advanced-stage disease (stage II-IV) or stage I and aaIPI score \u2265 2\n\n        -  Informed written consent\n\n      In clinical study A (Clin A) we are planning to evaluate the efficacy and the feasibility of\n      an intensified chemo-immunotherapy program including auto-SCT or RIC allo-SCT in advanced\n      stage PTCL pts \u2265 18 and < or = 60 years.\n\n      In clinical study B (Clin B) we intend to verify the efficacy and the feasibility of a\n      combined immuno-chemotherapy approach in a subset of elderly pts aged > 60  and < or = 75\n      years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u226518  <60 years (patients older than 60 years are excluded because of the\n             intensive chemotherapy and transplant procedures)\n\n          -  Histologically proven diagnosis of PTCL, including the following categories: PTCL-U\n             (peripheral T-cell lymphoma, unspecified), AILD-T (angioimmunoblastic-like T-cell\n             lymphoma), ALKneg ALCL (ALK-negative anaplastic large cell lymphoma),intestinal T -\n             NHL\n\n          -  Advanced stage disease (stage II-IV) or stage I and aaIPI score \u2265 2\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Histological PTCL subset other than PTCL-U, AILD-T ALCL-ALKneg, intestinal T - NHL\n\n          -  Central nervous system localization\n\n          -  Positive serologic markers for human immunodeficiency virus (HIV), hepatitis B virus\n             (HBV), and hepatitis C virus (HCV) infection\n\n          -  Serum bilirubin levels > 2 the upper normal limit\n\n          -  Clearance of creatinine < 50 ml/min\n\n          -  DLCO < 50%\n\n          -  Ejection fraction < 45% (or myocardial infarction in the last 12 months)\n\n          -  Pregnancy or lactation\n\n          -  Patient not agreeing to take adequate contraceptive measures during the study\n\n          -  Psychiatric disease\n\n          -  Any active, uncontrolled infection\n\n          -  Type I hypersensitivity or anaphylactic reactions to proteins drugs\n\n          -  Active secondary malignancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "92", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01679860", 
            "org_study_id": "PTCL-062006-004234-33"
        }, 
        "intervention": [
            {
                "arm_group_label": "Clin A", 
                "description": "Clin A:\nCHOP-Campath (CHOP-C) for 2 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO on days +1 to +5; Campath-1H (alemtuzumab) dose escalation 3-10-20mg IV days - 2, - 1, 0 (first CHOP-C) or 30mg SC day 0 (second CHOP-C). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on days + 1 and 21 (first and second CHOP-C).\nHYPER-C-HiDAM for 2 cycles: Methotrexate 1.5gr/m2 day +1; Cyclophosphamide 300mg/m2 every 12 hours days +2-3-4; ARA-C 2gr/m2 every 12 hours days +2-3-4; G-CSF 5\u03bccg/kg/day starting from day +5 until peripheral blood stem cell harvest\nMyeloablative regimen followed by autologous transplantation or Reduced intensity conditioning followed by allogeneic transplantation.", 
                "intervention_name": "Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT", 
                "intervention_type": "Procedure", 
                "other_name": "Mab - Campath (Alemtuzumab)"
            }, 
            {
                "arm_group_label": "Clin B", 
                "description": "Clin B:\nCHOP-Campath (CHOP-C) for 6 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO from day +1 to day +5\u00b8 Campath-1H (alemtuzumab) 3-10mg IV on days - 1 and 0 ( first CHOP-C course) or 10mg SC on day 0 (for the following 5 C-CHOP courses). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on day +1 of each CHOP-C course.", 
                "intervention_name": "Clin B (CHOP- CAMPATH) Chemo-immunotherapy", 
                "intervention_type": "Drug", 
                "other_name": "Mab- Campath (Alemtuzumab)"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Alemtuzumab", 
                "Campath 1G"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 3, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Orbassano", 
                        "country": "Italy", 
                        "state": "Torino", 
                        "zip": "10043"
                    }, 
                    "name": "Azienda Ospedaliera S. Luigi"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Alessandria", 
                        "country": "Italy", 
                        "zip": "15100"
                    }, 
                    "name": "Ospedale SS. Antonio e Biagio e Cesare Arrigo"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ancona", 
                        "country": "Italy", 
                        "zip": "62020"
                    }, 
                    "name": "University of Ancona - Division of Hematology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bergamo", 
                        "country": "Italy", 
                        "zip": "24128"
                    }, 
                    "name": "Ospedale Riuniti, Bergamo - Division of Hematology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bolzano", 
                        "country": "Italy", 
                        "zip": "39100"
                    }, 
                    "name": "Ospedale Generale Regionale Bolzano"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brescia", 
                        "country": "Italy", 
                        "zip": "25123"
                    }, 
                    "name": "Spedali Civili di Brescia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Catania", 
                        "country": "Italy", 
                        "zip": "94124"
                    }, 
                    "name": "Azienda Ospedale Vittorio Emanuele Ferrarorro S. Bambino- Universit\u00e0 di Catania"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cuneo", 
                        "country": "Italy", 
                        "zip": "12100"
                    }, 
                    "name": "Ospedale S. Croce - Division of Hematology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milan", 
                        "country": "Italy", 
                        "zip": "20133"
                    }, 
                    "name": "Division of Hematology - Fondazione IRCCS Istituto Nazionale Tumori"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milan", 
                        "country": "Italy", 
                        "zip": "20100"
                    }, 
                    "name": "Ospedale San Raffaele, Milano - Division of Hematology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "zip": "20122"
                    }, 
                    "name": "IRCCS Ospedale Maggiore Policlinico di Milano"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palermo", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale Cervello - Bone Marrow Transplantation Unit"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Potenza", 
                        "country": "Italy", 
                        "zip": "85100"
                    }, 
                    "name": "Ospedale San Carlo"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torino", 
                        "country": "Italy", 
                        "zip": "10126"
                    }, 
                    "name": "Universit\u00e0 di Torino- Azienda Ospedaliera S. Giovanni Battista"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torino", 
                        "country": "Italy", 
                        "zip": "10126"
                    }, 
                    "name": "Azienda OspedalieraSan Giovanni Battista"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Udine", 
                        "country": "Italy"
                    }, 
                    "name": "Policlinico Universitario Udine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Verona", 
                        "country": "Italy", 
                        "zip": "37134"
                    }, 
                    "name": "Azienda Ospedaliera Policlinico di Verona"
                }
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Intensive Chemo-immunotherapy as First-line Treatment in Adult Patients With Peripheral T-cell Lymphoma (PTCL)", 
        "overall_official": {
            "affiliation": "fondazione IRCCS istituto nazionale tumori Milano", 
            "last_name": "paolo corradini", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: The Italian Medicines Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "number of clinical responses", 
            "measure": "Efficacy", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01679860"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fondazione IRCCS Istituto Nazionale dei Tumori, Milano", 
            "investigator_full_name": "Paolo Corradini", 
            "investigator_title": "Director Hematology and BMT Unit", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "OS time is calculated from patients enrollment to death for all causes; censored cases are pts alive at the date of last follow-up assessment.", 
                "measure": "evaluation of OS (overall survival)", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "description": "DFS time is the interval between CR achievement and the first disease relapse or death regardless of the cause.Definition of disease response/progression will be performed according to the criteria published by Juweid et al.(J Clin Oncol. 2005; 23: 4652-61)", 
                "measure": "DFS (Disease Free Survival)", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "description": "TRM will be analysed by computing the corresponding crude cumulative incidence curve, considering disease-related death as competing event.", 
                "measure": "TRM (Treatment Related Mortality)", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }
        ], 
        "source": "Fondazione IRCCS Istituto Nazionale dei Tumori, Milano", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fondazione IRCCS Istituto Nazionale dei Tumori, Milano", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2006", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}